Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if the combination of sunitinib and
gemcitabine is effective in treating patients with metastatic renal cell carcinoma. The
safety of this combination will also be studied. Sunitinib is approved by the FDA for the
treatment of renal cell carcinoma. However, some patients' cancers do not respond to
treatment or stops responding after initially responding. Gemcitabine is a chemotherapy drug
that is approved by the FDA for the treatment of pancreatic cancer and several other cancers.
It is not approved for the treatment of renal cell carcinoma. Previous research has suggested
that combining gemcitabine with sunitinib may have some effectiveness in treating metastatic
renal cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Pfizer